Headache News and Research

Latest Headache News and Research

Modifying Oncolytic Adenoviruses to Target Pancreatic Cancer

Pancreatic cancer is one of the less common but deadliest cancers. Modified oncolytic adenoviruses represent an alternative to chemotherapy and targeted therapies, which have a high mortality rate.

9 Mar 2018

FDA approves new tests to detect tickborne parasite in human plasma and whole blood samples

The U.S. Food and Drug Administration today approved the Imugen Babesia microti Arrayed Fluorescent Immunoassay, for the detection of antibodies to Babesia microti (B. microti) in human plasma samples, and the Imugen Babesia microti Nucleic Acid Test (NAT), for the detection of B. microti DNA in human whole blood samples.

7 Mar 2018

Glass walls and headaches at Apple Park

Apple has a beautiful nearly all-glass office at Cupertino. It almost looks like a futuristic spaceship. But in reality, the all glass model is giving the employees a real and literal headache as they repeatedly bump into the glass walls.

5 Mar 2018

Lassa fever strikes in Nigeria - high rates of fatality with no cure and no vaccine

Nigeria has been affected with an outbreak of the deadly Lassa fever since the start of this year. This disease typically has a high rate of fatality, no known cure and no vaccines have been developed against it yet. This is an unprecedented outbreak of this disease that is spreading faster than before. It is infecting more individuals than health workers can handle with their limited resources, say official sources.

5 Mar 2018

UC receives $1.75 million grant for epilepsy research

Research scientist Jianxiong Jiang, PhD, doesn't just want to treat acquired epilepsy...he hopes to prevent it.

27 Feb 2018

New data from VOYAGE 2 trial shows promising results for Janssen’s guselkumab treatment

The Janssen Pharmaceutical Companies of Johnson & Johnson announced today new data that showed a vast majority of patients with moderate to severe plaque psoriasis receiving TREMFYA (guselkumab), who achieved at least a 90 percent improvement in the Psoriasis Area and Severity Index (PASI 90) at week 28, maintained a PASI 90 response with continuous treatment through week 72.

From J&J Innovative Medicine 22 Feb 2018

Scientists uncover genetic cause behind typhoid's antibiotic resistance

The genetic cause behind a strain of typhoid's resistance to five classes of antibiotics has been uncovered by scientists at the Wellcome Sanger Institute and their collaborators at Public Health England and Aga Khan University, Pakistan.

20 Feb 2018

Study finds decline in number of clinical trials funded by NIH

The number of clinical trials funded by the National Institutes of Health has declined since 2005, according to a new study by researchers at the Johns Hopkins Bloomberg School of Public Health. During the same period, average trial sizes were observed to be smaller with only 10 percent of trials enrolling more than 500 participants.

13 Feb 2018

Migraines increase the risk cardiovascular diseases, finds study

Frequent migraines may increase the risk of cardiovascular diseases such as heart attacks, stroke, blood clots and an irregular heartbeat, suggests new study.

2 Feb 2018

Flu can be spread without coughs and sneezes

A study published yesterday in the Proceedings of the National Academy of Sciences reports that it is easier to spread the influenza virus than was previously thought.

19 Jan 2018

Pretreatment improves outcomes in high-risk stage 3 melanoma, study shows

A pair of targeted therapies given before and after surgery for melanoma produced at least a six-fold increase in time to progression compared to standard-of-care surgery for patients with stage 3 disease, researchers at The University of Texas MD Anderson Cancer Center report in Lancet Oncology.

18 Jan 2018

FDA grants approval for first drug to treat inherited breast cancer

The U.S. Food and Drug Administration today expanded the approved use of Lynparza (olaparib tablets) to include the treatment of patients with certain types of breast cancer that have spread (metastasized) and whose tumors have a specific inherited (germline) genetic mutation, making it the first drug in its class (PARP inhibitor) approved to treat breast cancer, and it is the first time any drug has been approved to treat certain patients with metastatic breast cancer who have a "BRCA" gene mutation.

15 Jan 2018

U.S. FDA approves first drug for patients with germline BRCA-mutated metastatic breast cancer

AstraZeneca and Merck, known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration has approved LYNPARZA (olaparib) for use in patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm), human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer who have been previously treated with chemotherapy in the neoadjuvant, adjuvant or metastatic setting.

12 Jan 2018

UPM researchers successfully simulate real-time migraine prediction system

UPM researchers, in collaboration with UCM and Hospital Universitario de la Princesa, have successfully simulated a system that alert patients to an incoming migraine crisis in real time. According to the simulation results, the reliability of this system is over 75%.

11 Jan 2018

Migraine surgery leads to significant improvements in everyday functioning and coping ability

In addition to reducing headache frequency and severity, surgical treatment for migraine leads to significant improvements in everyday functioning and coping ability, according to a study in the January issue of Plastic and Reconstructive Surgery®, the official medical journal of the American Society of Plastic Surgeons.

3 Jan 2018

Novartis announces FDA approval of its first and only CML therapy with TFR data in product label

Novartis announced today that the US Food and Drug Administration (FDA) approved the inclusion of Treatment-free Remission (TFR) data in the Tasigna® (nilotinib) US product label.

26 Dec 2017

Terror survivors have increased risk of frequent migraine, tension headaches

Survivors of a terror attack have an increased risk of frequent migraine and tension headaches after the attack, according to a study published in the December 13, 2017, online issue of Neurology®, the medical journal of the American Academy of Neurology.

14 Dec 2017